Evidence map›Paper›PMID 36897548›Full record

ArticleHuman cell2023

Prognostic and functional roles of EIF4G1 in lung squamous cell carcinoma.

Baoxin Bai, Lin Dong, Minghao Feng, Zhiwen Zhang, Ying Lu, Zengguang Xu, Yali Liu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Knockdown ofFrontiers in pharmacology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Baoxin Bai *Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200092, China.ORCID http://orcid.org/0000-0003-3766-3628
Lin Dong *Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200092, China.
Minghao FengResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200092, China.
Zhiwen ZhangResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200092, China.
Ying LuResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200092, China.
Zengguang XuResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200092, China. xuzg1998@tongji.edu.cn.ORCID http://orcid.org/0000-0002-4814-9635
Yali LiuResearch Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, 200092, China. yaliliuliu@163.com.
Shanghai East Hospital · CNHubei University of Medicine · CNTongji University · CN

Funding

National Natural Science Foundation of China 81972183Shiyan Science and technology 21Y05
6 · The paper itself

Abstract

Eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) is highly expressed in many cancers and affects their occurrence and development. However, the effect of EIF4G1 on the prognosis, biological function and the relevant mechanism in lung squamous cell carcinoma (LSCC) is unclear. Through clinical cases, Cox's proportional hazard model and Kaplan-Meier plotter survival analysis, we find the expression levels of EIF4G1 are dependent on age and clinical stage, high expression of EIF4G1 could be used to predict the overall survival of LSCC patients. LSCC cell line NCI-H1703, NCI-H226 and SK-MES-1infected with EIF4G1 siRNA are used to detect the function of EIF4G1 with cell proliferation and tumorigenesis in vivo and vitro. The data show that EIF4G1 promotes tumor cell proliferation and the G1/S transition of cell cycle in LSCC, then the biological function of LSCC is effected by the AKT/mTOR pathway. Above all, these results have demonstrated that EIF4G1 promotes LSCC cell proliferation and may represent an indicator of prognosis in LSCC.

Indexed as

Carcinoma, Non-Small-Cell LungCarcinoma, Squamous CellLung NeoplasmsCell Line, TumorCell ProliferationEukaryotic Initiation Factor-4GGene Expression Regulation, NeoplasticHumansLungPrognosisEIF4G1 protein, humanEukaryotic Initiation Factor-4GEIF4G1Functional roleLSCCPrognosis

Identifiers

PMID36897548
PMCPMC10110680
OpenAlexW4323811735

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.